Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics
Zhejiang Conba Pharmaceutical Co., Ltd. (SHA: 600572) announced it has entered into a strategic licensing...
Company
Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)
Jacobio Pharmaceuticals (HKG: 1167) announced that its portfolio company, Jacobio-Raikang, has received National Medical Products...
Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma
Haixi Pharmaceutical announced it has officially initiated its Phase III clinical trial (CTR20261818) evaluating C019199,...
Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
Astellas Pharma Inc. (TYO: 4503) announced that China’s National Medical Products Administration (NMPA) has accepted...
Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced that China’s National Medical Products Administration (NMPA)...
Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced positive results from its Phase 2 clinical...
Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ) has...
Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Changchun High & New Technology Industry (Group) Inc. (SHE: 000661) announced that China’s National Medical...
Johnson & Johnson Secures FDA Approval for Dual Energy THERMOCOOL SMARTTOUCH SF Platform, First Single-Catheter Solution Combining Radiofrequency and Pulsed Field Ablation
Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA)...
AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk
AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for...
Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare
Xenovector, a pioneering biotechnology company in xenotransplantation, has announced a deep strategic cooperation with Jilin...
Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline
Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) and Tigermed Consulting Co., Ltd. (SHE: 300347, HKG:...
Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement
Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its proprietary transvenous tricuspid valve replacement system,...
Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that its clinical trial application...
Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its proprietary SHR-4685 has...
Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus
Hangzhou Qihan Biotech Engineering Life (“Qihan Biotech”) announced that its QT-019C cell injection has received...
Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis
Insilico Medicine (HKG: 3696) announced the initiation of a Phase 3 clinical trial (CTR20262475, NCT07687459)...
Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights
Transcenta Holding Limited (HKG: 6628) announced it will return select collaborative products to Eli Lilly...
Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced the formal establishment of a Joint Laboratory...
Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million
Nanjing Pharmaceutical Co., Ltd. (SHA: 600713) announced that its holding subsidiary, Nanjing Pharmaceutical Group Qianglian...